ACAD - ACADIA Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

ACADIA Pharmaceuticals Inc.

3611 Valley Centre Drive
Suite 300
San Diego, CA 92130
United States

Full Time Employees490

Key Executives

NameTitlePayExercisedYear Born
Mr. Stephen R. DavisCEO & Director1.23MN/A1961
Dr. Srdjan R. StankovicPres878.37kN/A1957
Mr. Austin D. KimExec. VP, Gen. Counsel & Sec.529.11kN/A1964
Mr. Michael J. YangExec. VP & Chief Commercial Officer892.5kN/A1962
Ms. Elena H. Ridloff C.F.A., CFAExec. VP, CFO & Principal Accounting OfficerN/AN/A1980
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Corporate Governance

ACADIA Pharmaceuticals Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.